William B. Graham

William B. Graham did not found Baxter, and he was not a physician. He was a University of Chicago chemist who had drifted into patent law, and when he took over what was then Baxter Laboratories in 1953 it was a small Midwestern maker of sterile intravenous solutions, packed in the vacuum glass bottles that had carried the company through the Depression ^[1][6]. Over the next twenty-seven years Graham did something rarer than invention: he built an organization whose entire purpose was to bring scientific risks, the artificial kidney, the plastic blood bag, the flexible IV container, out of the laboratory and into routine hospital use, and he made that mission pay ^[3][5]. By the time he stepped down as chief executive in 1980, sales had quadrupled to roughly $1 billion, and the company had posted earnings growth of about 21 percent a year for twenty-four consecutive years, one of the longest such records in American industry ^[4][6].

The defining decision came early. In the mid-1950s Dr. Willem Kolff, the Dutch émigré who had built the first working artificial kidney out of cellophane sausage casing and, famously, a Maytag washing machine tub, was looking for a manufacturer willing to mass-produce a cheap, disposable version of his twin-coil dialyzer ^[5][7]. Few wanted the risk; dialysis was exotic, the market unproven. Graham's Baxter took it on, and on October 30, 1956 the Travenol division in Morton Grove, Illinois, launched the first commercially built, disposable artificial kidney, its coil and bloodlines selling for fifty-nine dollars ^[5][7]. It was the moment a solution company became a device company, and it set the pattern for everything after ^[3][6].

Graham institutionalized that pattern. Where the founder, Ralph Falk, had built a research function, Graham poured money into it and organized the company to convert discoveries into products, Hyland Laboratories' blood plasma fractions (acquired 1952), the Fenwal plastic blood-collection systems that came with the 1959 purchase of Fenwal, the first concentrated clotting factor that transformed the lives of hemophiliacs, and in 1970 Viaflex, the first flexible plastic IV bag, which displaced the breakable glass bottle that had defined the industry for a generation ^[1][6]. Each was a 'first,' and each opened a market that competitors then had to chase ^[3].

He was also a builder of the modern corporation. In 1961 he took Baxter public on the New York Stock Exchange, and the steadily compounding earnings produced a long series of stock splits that made early shareholders wealthy ^[1][6]. In 1963 he made one of his boldest moves, ending the thirty-year arrangement under which American Hospital Supply Corporation had distributed Baxter's products, and building Baxter's own national sales force, a wrenching change that gave Graham direct control of how his products reached the hospital ^[1][6]. The company entered the Fortune 500 in 1971 ^[6].

Graham's Baxter was not flashy. He shunned personal publicity, left almost no quotable bravado behind, and ran the company as a disciplined compounding machine rather than a personality cult ^[2][6]. His genius lay in matching long-horizon scientific bets to the patient, methodical R&D and financial structure that could carry them, and in understanding that in medicine, being first with a genuinely needed product was the most durable competitive advantage of all ^[3][6]. The artificial kidney, the blood bag, and the flexible IV container are now so ordinary that no one thinks of them as inventions, which is precisely the measure of his success ^[3][5].

William Blair Graham was born in 1911 in Illinois, and his entire formation was bound up with one institution: the University of Chicago ^[3][6]. He entered as an undergraduate and graduated in 1932 with a B.S. in chemistry, finishing first in his class and winning election to Phi Beta Kappa and Sigma Xi ^[1][6]. He stayed on for two years of honors graduate work in chemistry, studying under the future Nobel laureate Harold Urey, the discoverer of deuterium, an apprenticeship in serious science that would shape how Graham later thought about industrial research ^[1][6].

Then he changed course. Rather than complete a doctorate in chemistry, Graham entered the University of Chicago Law School and took his J.D. cum laude, and he went into practice as a patent lawyer, a hybrid training in science and intellectual property that was almost ideally suited to a company whose business would be turning novel medical inventions into protected, marketable products ^[1][6]. He practiced patent law until 1945, when, at the age of thirty-three, he joined Baxter Laboratories as a vice president and manager ^[1][6].

Baxter itself was young and small. It had been founded in 1931 by Dr. Donald Baxter to manufacture sterile intravenous solutions, a real innovation at a time when hospital-mixed IV fluids were of dangerously variable quality, and Dr. Ralph Falk had bought out Baxter's interest in 1935 and established the company's research arm ^[1][6]. When Falk handed Graham the chief executive's role in 1953, he was entrusting the firm to a man with no medical degree and only eight years inside it, but with exactly the blend of scientific literacy and legal-commercial discipline the next phase would demand ^[1][6].

The products William Graham brought to market are now so ordinary that their origins are invisible. The disposable artificial kidney made routine dialysis possible and helped lay the groundwork for the modern treatment of kidney failure ^[10]; the plastic blood bag remade blood banking; the flexible IV container became a global standard; and the first clotting factors changed what it meant to live with hemophilia ^[3][5][6]. Under Graham, Baxter grew from a small regional solutions maker into a Fortune 500 international healthcare company, and the growth model he established, long-term R&D bets converted into market-defining firsts, carried the company for decades after he left the chief executive's chair in 1980 ^[4][6].

Graham remained tied to the University of Chicago for life, serving as a trustee and lecturer, and in 1997 he and his wife Catherine gave the university $10 million; its continuing-studies division was renamed the William B. and Catherine V. Graham School of General Studies in their honor ^[1][3]. Harvard Business School named him among the great American business leaders of the twentieth century, and the Baxter International Foundation endowed the William B. Graham Prize for Health Services Research in his name ^[3][6]. When he died in 2006 at ninety-four, Baxter, by then a roughly $10-billion enterprise, credited him with having 'changed the course of modern healthcare' ^[2][3].